NEWS
Annovis to Highlight Buntanetap's Alzheimer's Research Progress with Presentations at CTAD 2024
Annovis Bio Inc. (NYSE: ANVS) announced it will present two scientific posters at the 17th Clinical Trials on Alzheimer's Disease (CTAD) conference in Madrid, Spain, from October 29 to November 1, 2024. The presentations will highlight the progress of buntanetap, the company's drug candidate for neurodegenerative disorders like Alzheimer's and Parkinson's disease.
Dr. Maria Maccecchini, President and CEO of Annovis Bio, will present two posters:
Poster LP023: 'Efficacy of Buntanetap in Early AD and APOE4 Phase 2/3 Alzheimer's Patients'
Poster LP074: 'Biomarker Data Showed Buntanetap Reduced Neurotoxic Proteins, Improved Axonal Integrity, Reduced Inflammation, and Neuronal Functions in Alzheimer's Clinical Studies'
Dr. Maria Maccecchini, President and CEO of Annovis Bio, will present two posters:
Poster LP023: 'Efficacy of Buntanetap in Early AD and APOE4 Phase 2/3 Alzheimer's Patients'
Poster LP074: 'Biomarker Data Showed Buntanetap Reduced Neurotoxic Proteins, Improved Axonal Integrity, Reduced Inflammation, and Neuronal Functions in Alzheimer's Clinical Studies'
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2879Followers
108Following
30KVisitors
Follow